Login to Your Account

VEGF Trap Fizzles, and Yet . . .

Sentiment 'Swayze' Other Way in Pancreatic; Hopes Escalating

By Randy Osborne

Monday, September 21, 2009
Word this month that Regeneron Pharmaceuticals Inc. and partner Sanofi-Aventis Group decided to quit their Phase III trial with aflibercept (VEGF Trap) for first-line metastatic pancreatic cancer put new focus on the grim, quick-spreading tumor type, much in the news as a result of actor Patrick Swayze's death last week.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription